WW International announced a new Wegovy subscription program for its Med+ members on March 31 2026. The program, part of an expanded collaboration with Novo Nordisk, allows members to pre‑pay for three, six, or twelve months of Wegovy pens and pills at discounted rates that are the lowest available self‑pay price for doses not covered by limited‑time offers.
The subscription options provide savings of up to $100 per month on Wegovy pens and $50 per month on Wegovy pills compared with the standard self‑pay price. When fully utilized, the program can deliver annual savings of up to $1,200 for the injection and $600 for the pill. The plan covers all Wegovy pen doses and the 9 mg and 25 mg Wegovy pill formulations.
In addition to the subscription discounts, the announcement highlighted a limited‑time offer that sets the starting dose of the Wegovy pill at $149 per month. The subscription pricing is positioned as the lowest cost option for Med+ members who are not eligible for the introductory offer, ensuring predictable and affordable access to FDA‑approved GLP‑1 therapy.
WW’s clinical business has grown sharply, with a 32% increase in clinical revenue in Q4 2025, while its behavioral segment saw a 17% decline. The new pricing strategy is intended to accelerate subscriber growth in the clinical arm by combining medication access with WW’s behavioral support platform. CEO Tara Comonte emphasized the company’s evolution in the GLP‑1 era, while Chief Commercial Officer Scott Honken highlighted the importance of affordability and access. Novo Nordisk’s Senior Vice President for Marketing and Patient Solutions, Ed Cinca, noted the shared mission to help people with obesity and the goal of bringing transparency and predictability to treatment.
The partnership with Novo Nordisk aligns with the company’s broader strategy to capitalize on the rapidly expanding GLP‑1 market. WW’s recent emergence from Chapter 11 has freed up capital for strategic investments, and the new subscription pricing is expected to boost clinical revenue. However, the company’s significant debt burden remains a headwind, underscoring the need for continued cost discipline as it expands its clinical footprint.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.